Angiotensin inhibitors for hypertension.
Inhibition of the angiotensin-converting enzyme emerges as a new promising approach to the treatment of hypertension. The intravenously administered teprotide appears to be suitable as a diagnostic test and for initial treatment of certain hypertensive emergencies. The oral inhibitor captopril is effective for chronic maintenance of blood pressure control in various types of hypertension but has been associated with a number of adverse reactions.
D000284:Administration, Oral; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007275:Injections, Intravenous; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism; D013722:Teprotide / Q000008:administration & dosage / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D000804:Angiotensin II; D011392:Proline; D002216:Captopril; D012964:Sodium; D013722:Teprotide; D012083:Renin